The DISCOVER-1 trial
Sunday 10 November: 11:00–12:30, Hall B1, Georgia World Congress Center, Atlanta, USA
Presenter: Atul Deodhar, Oregon Health & Science University, Portland, USA
The DISCOVER-1 trial includes adults with active psoriatic arthritis who were either biologic-naïve or had previously been treated with tumor necrosis factor inhibitors. Participants were randomly assigned to receive 48 weeks of treatment with either guselkumab 100 mg every 4 weeks, 100 mg every 8 weeks (after loading doses at weeks 0 and 4), or placebo for 24 weeks followed by guselkumab 100 mg every 4 weeks for the remaining 24 weeks.
The investigators will present the results of the primary endpoint analysis – ACR20 response rates at week 24 – as well as a number of secondary endpoints and safety data.
What our Advisory Board said:
This will provide the first phase III data in psoriatic arthritis (PsA) for a p19/anti-IL23 antibody. These are being used increasingly frequently in dermatology practice for psoriasis. It is important to assess the efficacy on musculoskeletal symptoms as well as skin disease, in order to help choose biologics optimally for our patients with psoriasis and PsA.